172 related articles for article (PubMed ID: 33769436)
1. Prognostic Significance of CD30 in Transformed Mycosis Fungoides.
Travaglino A; Russo D; Varricchio S; Pignatiello S; Baldo A; Picardi M; Pane F; Mascolo M
Am J Clin Pathol; 2021 Aug; 156(3):350-355. PubMed ID: 33769436
[TBL] [Abstract][Full Text] [Related]
2. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
[TBL] [Abstract][Full Text] [Related]
3. Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides.
Lai P; Liu F; Liu X; Sun J; Wang Y
Front Immunol; 2023; 14():1270365. PubMed ID: 37790936
[TBL] [Abstract][Full Text] [Related]
4. CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right.
Kadin ME
Br J Dermatol; 2015 Jun; 172(6):1478-1479. PubMed ID: 26036155
[No Abstract] [Full Text] [Related]
5. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.
Simo OC; Warren SJ; Mark L; Hoffmann K; Alomari AK
Int J Dermatol; 2019 Jul; 58(7):800-805. PubMed ID: 30520526
[TBL] [Abstract][Full Text] [Related]
6. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
7. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
[TBL] [Abstract][Full Text] [Related]
8. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma.
Gao C; McCormack CJ; van der Weyden C; Twigger R; Buelens O; Lade S; Khoo C; Campbell BA; Goh M; McKelvie P; Prince HM
J Am Acad Dermatol; 2021 Jan; 84(1):185-187. PubMed ID: 32334059
[No Abstract] [Full Text] [Related]
9. Mycosis fungoides with CD30-positive cells in the epidermis.
Wu H; Telang GH; Lessin SR; Vonderheid EC
Am J Dermatopathol; 2000 Jun; 22(3):212-6. PubMed ID: 10871063
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
11. A review of CD30 expression in cutaneous neoplasms.
Kampa F; Mitteldorf C
J Cutan Pathol; 2021 Apr; 48(4):495-510. PubMed ID: 33047376
[TBL] [Abstract][Full Text] [Related]
12. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
13. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan SS; Hong EK; Kim YH; Kim J
J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
[TBL] [Abstract][Full Text] [Related]
14. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
16. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
17. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
[TBL] [Abstract][Full Text] [Related]
18. Mycosis fungoides with CD30-positive large-cell transformation clinically mimicking scarring alopecia.
Bidier M; Pushkarevskaya A; Enk A; Hartmann M; Toberer F
J Dtsch Dermatol Ges; 2017 Oct; 15(10):1021-1023. PubMed ID: 28834192
[No Abstract] [Full Text] [Related]
19. CD4/CD8 double-negative early-stage mycosis fungoides with CD30 expression.
Shon U; Yun DK; Seong GH; Park BC; Kim MH; Lee DY
J Cutan Pathol; 2021 Apr; 48(4):587-589. PubMed ID: 32789870
[No Abstract] [Full Text] [Related]
20. Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides.
Harrington CR; Guillén DR; Pandya AG
Clin Lymphoma Myeloma; 2007 Jul; 7(7):480-5. PubMed ID: 17875239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
